In vivo mouse myocardial P-31 MRS using three-dimensional image-selected in vivo spectroscopy (3D ISIS): technical considerations and biochemical validations

Citation for published version (APA):

DOI:
10.1002/nbm.3371

Document status and date:
Published: 01/10/2015

Document Version:
Publisher’s PDF, also known as Version of Record (includes final page, issue and volume numbers)

Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page numbers.

Link to publication

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above, please follow below link for the End User Agreement:
www.tue.nl/taverne

Take down policy
If you believe that this document breaches copyright please contact us at:
openaccess@tue.nl
providing details and we will investigate your claim.

Download date: 22. Oct. 2023
**In vivo** mouse myocardial $^{31}$P MRS using three-dimensional image-selected **in vivo** spectroscopy (3D ISIS): technical considerations and biochemical validations

Adrianus J. Bakermans$^{a,b,*}$, Desiree Abdurrachim$^{a,*}$, Bastiaan J. van Nierop$^a$, Anneke Koeman$^c$, Inge van der Kroon$^a$, Antonius Baartscheer$^d$, Cees A. Schumacher$^d$, Gustav J. Strijkers$^{a,e}$, Sander M. Houten$^f$, Coert J. Zuurbier$^c$, Klaas Nicolay$^a$ and Jeanine J. Prompers$^a$

$^{31}$P MRS provides a unique non-invasive window into myocardial energy homeostasis. Mouse models of cardiac disease are widely used in preclinical studies, but the application of $^{31}$P MRS in the **in vivo** mouse heart has been limited. The small-sized, fast-beating mouse heart imposes challenges regarding localized signal acquisition devoid of contamination with signal originating from surrounding tissues. Here, we report the implementation and validation of three-dimensional image-selected $^{31}$P MRS for localized $^{31}$P MRS of the **in vivo** mouse heart at 9.4 T. Cardiac $^{31}$P MR spectra were acquired **in vivo** in healthy mice ($n = 9$) and in transverse aortic constricted (TAC) mice ($n = 8$) using respiratory-gated, cardiac-triggered 3D ISIS. Localization and potential signal contamination were assessed with $^{31}$P MR experiments in the anterior myocardial wall, liver, skeletal muscle and blood. For healthy hearts, results were validated against **ex vivo** biochemical assays. Effects of isoflurane anesthesia were assessed by measuring **in vivo** hemodynamics and blood gases. The myocardial energy status, assessed via the phosphocreatine (PCr) to adenosine 5′-triphosphate (ATP) ratio, was approximately 25% lower in TAC mice compared with controls ($0.76 \pm 0.13$ versus $1.00 \pm 0.15; P < 0.01$). Localization with one-dimensional (1D) ISIS resulted in two-fold higher PCr/ATP ratios than measured with 3D ISIS, because of the high PCr levels of chest skeletal muscle that contaminate the 1D ISIS measurements. **Ex vivo** determinations of the myocardial PCr/ATP ratio ($0.94 \pm 0.24; n = 8$) confirmed the **in vivo** observations in control mice. Heart rate (497 ± 76 beats/min), mean arterial pressure (90 ± 3.3 mmHg) and blood oxygen saturation (96.2 ± 0.6%) during the experimental conditions of **in vivo** $^{31}$P MRS were within the normal physiological range. Our results show that respiratory-gated, cardiac-triggered 3D ISIS allows for non-invasive assessments of **in vivo** mouse myocardial energy homeostasis with $^{31}$P MRS under physiological conditions. Copyright © 2015 John Wiley & Sons, Ltd.

**Keywords:** energy metabolism; heart; ISIS; mouse; $^{31}$P MRS; transverse aortic constriction (TAC)

---

**Abbreviations used:** 1D, 2D, 3D, one-, two-, three-dimensional; $\alpha$, $\beta$, $\gamma$-ATP, $\alpha$, $\beta$, $\gamma$-phosphate groups in adenosine 5′-triphosphate; CSI, chemical shift imaging; 2,3-DPG, 2,3-diphosphoglycerate; ECG, electrocardiogram; EDTA, ethylenediaminetetraacetic acid; EDV, end-diastolic volume; EF, ejection fraction; ESV, end-systolic volume; ISIS, image-selected in vivo spectroscopy; LV, left ventricle/left ventricular; LW, line width; MAP, mean arterial pressure; NA, number of averages; PCr, phosphocreatine; PDE, phosphodiesterases; Pi, inorganic phosphate; SD, standard deviation; SNR, signal-to-noise ratio; SV, stroke volume; TAC, transverse aortic constriction/transverse aortic constricted.

---

$^*$ These authors contributed equally to this work.

---

Correspondence to: A. J. Bakermans, Department of Radiology (Z0-180), Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands

E-mail: a.j.bakermans@amc.uva.nl

---


Biomedical NMR, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands

---

A. J. Bakermans

Department of Radiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands

---

A. Koeman, C. J. Zuurbier

Laboratory of Experimental Intensive Care and Anesthesiology, Department of Anesthesiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands

---

d A. Baartscheer, C. A. Schumacher

Experimental Cardiology, Heart Failure Research Center, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands

---

G. J. Strijkers

Biomedical Engineering and Physics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands

---

S. M. Houten

Laboratory Genetic Metabolic Diseases, Department of Clinical Chemistry, and Department of Pediatrics, Emma Children’s Hospital, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands

---

These authors contributed equally to this work.
INTRODUCTION

Mouse models are widely used in preclinical studies on the pathogenesis of cardiomyopathies. Disturbed myocardial energy metabolism has been identified as an important contributor to the development of cardiomyopathy (1). The assessment of the myocardial energy status is therefore instrumental in the characterization of disease progression or treatment response. The high-energy phosphates adenosine 5′-triphosphate (ATP) and phosphocreatine (PCr) are essential for providing energy for cellular processes, such as sarcomere contraction in cardiomyocytes, and for energy transport and buffering. The inherent instability of high-energy phosphates compromises the accurate assessment of the myocardial energy status with biochemical techniques, which require disruptive or terminal biopsies, precluding longitudinal in vivo investigations. Many MRI and, to a lesser extent, MRS methods have been introduced to study the in vivo mouse heart non-invasively (2–4). These methods allow for longitudinal studies of disease progression and assessments of the effects of therapeutic strategies.

31P MRS is the only method that provides a non-invasive window into in vivo high-energy phosphates (1). Localized signal acquisition is essential to restrict the spectrum obtained to the heart, excluding signal from nearby liver tissue or chest skeletal muscle. Localization methods for 31P MRS include single-voxel as well as chemical shift imaging (CSI) approaches. 31P CSI allows for an assessment of regional differences in myocardial energy status (5), but is susceptible to intervoxel signal contamination as a result of Fourier bleeding (6). In contrast, single-voxel localization with three-dimensional image-selected in vivo spectroscopy (3D ISIS) (7) leads to a better defined voxel shape (8), but the voxel size is typically much larger compared with CSI, and commonly includes the whole left ventricle (LV) (9).

Localized 31P MRS of the in vivo mouse heart is very challenging because of the small organ size (~100 mg), high heart rate (~500 beats/min) and intrinsically low sensitivity of 31P MRS. Methods for in vivo one-dimensional (1D) and two-dimensional (2D) 31P CSI of the mouse heart were initially demonstrated in healthy mice (10) and in a transgenic mouse model for cardiomyopathy (11). These experiments were performed at a constant TR, which is essential for reliable signal quantification. None of these methods used cardiac triggering or respiratory gating to account for physiological motion of the tissue of interest. Together with the effects of Fourier bleeding in CSI methods, tissue displacement could lead to contamination of the spectrum with signal from the liver, blood and/or chest skeletal muscle.

One early study describes the application of cardiac-triggered 3D ISIS for in vivo 31P MRS of the mouse heart (9). Although cardiac triggering was used in these experiments to synchronize the acquisitions with the cardiac cycle, no measures were taken to ensure a constant TR. When applying ISIS under partially saturated conditions (i.e. if TR < 5 × T1), variations in TR can lead to signal contamination (12,13), as well as modulations of signal amplitudes, as a result of T1-dependent partial saturation effects. These early experiments were performed at 2.35 T and required a lengthy experimental time of nearly 3 h (9). At higher field strengths, the scan time can possibly be reduced to acceptable values whilst maintaining sufficient signal-to-noise ratio (SNR) for signal quantification.

Here, we report the implementation of 3D ISIS for single-voxel localized 31P MRS of the in vivo mouse heart at 9.4 T. Because 3D ISIS is a multi-shot localization method, and hence particularly sensitive to motion artifacts, we employed both respiratory gating and cardiac triggering whilst maintaining a steady state of magnetization with dummy excitations during respiratory gates to ensure a constant TR (14). Results were validated against ex vivo biochemical assays of myocardial PCr and ATP concentrations. Hemodynamics and blood gases were measured to assess the potential effects of isoflurane anesthesia on the cardiovascular physiology. To demonstrate suitability for cardiac applications, the method was applied to a well-characterized mouse model of heart failure (15,16).

METHODS

Animals

All procedures were approved by the Animal Ethics Committee of Maastricht University (Maastricht, the Netherlands). Male C57BL/6 mice (n = 8; body weight, 26.2 ± 2.6 g) underwent transverse aortic constriction (TAC) surgery as described previously (17). Anesthesia was induced using 2–3% isoflurane in a 0.4-L/min flow of 1 : 1 O2 : medical air, after which mice were intubated for mechanical ventilation. Analgesia was provided using buprenorphine (0.1 mg/kg, subcutaneous). An incision was made above the first intercostal space to gain access to the aortic arch. The aorta was tied off with a 27G needle between the innominate artery and the left common carotid artery with a 6-0 silk suture. Subsequent needle removal left an aortic stenosis, inducing LV pressure overload. The chest was closed and the intubation tube was removed to allow full recovery. Seven weeks after surgery, MR data were acquired as described below. Healthy mice (n = 9; body weight, 24.4 ± 2.0 g) served as controls. Following the MR measurements, anesthetized mice were sacrificed by exsanguination. Blood was collected in ethylenediaminetetraacetic acid (EDTA) tubes for ex vivo analysis with 31P MRS.

MR protocol

Mice were anesthetized with 2–3% isoflurane in a 0.4-L/min flow of medical air and positioned prone in a purpose-built support cradle above a custom-built, actively decoupled, two-turn 31P surface coil (Ø = 15 mm) for signal reception. Anesthesia was maintained with 1.2–1.6% isoflurane in a continuous flow of 0.4 L/min of medical air. The front paws were taped onto gold-coated electrocardiogram (ECG) electrodes integrated in the anesthesia mask. A respiratory balloon was positioned underneath the lower abdomen. Vital signs were monitored and used for MR gating and triggering by the SA Monitoring and Gating System 1025 (Small Animal Instruments, Stony Brook, NY, USA). Mouse body temperature was maintained using a heating pad with integrated warm water flow, and monitored with an external abdominal fiber-optic probe. The set-up was inserted into a horizontal-bore 9.4-T magnet (Magnex Scientific, Yarnton, Oxford, UK), interfaced to a Bruker Avance III console (Bruker Biospin MRI, Ettlingen, Germany) and controlled by the ParaVision 5.0 software package (Bruker Biospin). The system was equipped with a 740-mT/m gradient set and a volume coil (Ø = 54 mm) composed of a quadrature 1H birdcage resonator and a linear 31P birdcage resonator (RAPID Biomedical, Rimpar, Germany), used for 1H MRI and shimming, and for radiofrequency transmission for 31P MRS, respectively.
Scout $^1$H MR images were acquired to confirm the positioning of the heart within the sensitive area of the $^{31}$P surface coil. A segmented, prospectively cardiac-triggered, respiratory-gated, fast low-angle shot sequence was used to acquire a cine $^1$H MR image series of 16–18 frames per cardiac cycle. Four 1-mm LV short-axis slices were complemented with four- and two-chamber long-axis views, and used for the quantification of LV function and morphology, as well as for anatomical reference during 3D ISIS voxel planning for localized $^{31}$P MRS. The imaging parameters were as follows: field of view, $30 \times 30$ mm$^2$; matrix, $128 \times 128$; TE = 1.8 ms; TR = 7 ms; flip angle, 15°; number of averages (NA) = 4. The total acquisition time was approximately 20 min.

Subsequently, an $11 \times 11 \times 11$-mm$^3$ voxel in the sensitive area of the surface coil was shimmed manually by minimization of the $^1$H$_2$O line width (LW), acquired with a respiratory-gated, cardiac-triggered, point-resolved spectroscopy sequence (18). Calibration of the $^{31}$P sinc excitation pulse (pulse length, 1.2 ms; bandwidth, 32.0 ppm) was performed by varying the pulse power to achieve the maximal signal from a spherical phantom (Ø = 5 mm; $15 \text{M}$ phosphoric acid) positioned underneath the $^{31}$P surface coil. After removal of the phantom, unlocalized pulse-acquire $^{31}$P MR spectra were obtained from a subset of animals ($n = 5$ per group) to assess metabolite $T_1$ values using conventional saturation recovery experiments. The parameters were as follows: 1.2-ms 90° sinc excitation pulse; bandwidth, 32.0 ppm; $\gamma$-ATP on resonance; TR = 500, 1000, 2000, 4000, 6000 and 15 000 ms; NA = 1024–32.

Next, a respiratory-gated, cardiac-triggered 3D ISIS sequence was used for localized cardiac $^{31}$P MRS. Dependent on heart size, a 3D ISIS voxel (TAC: $326 \pm 43$ mL versus control: $175 \pm 8.8$ mL) was positioned to enclose the end-diastolic LV, carefully excluding the liver and chest skeletal muscle (Fig. 1A, B). The 3D ISIS parameters were as follows: TR = 2 s; NA = 768 (96 3D ISIS cycles) preceded by one dummy cycle; 6.25-ms 180° adiabatic hyperbolic secant inversion pulses (bandwidth, 37.5 ppm); 1.2-ms 90° sinc excitation pulse (bandwidth, 32.0 ppm); $\gamma$-ATP on resonance; 2048 acquisition points. Although the excitation pulse was calibrated, the potential effect of spatial contamination by so-called ‘$T_1$ smearing’ as a result of inhomogeneous excitation pulses (19) was further minimized by choosing the least-optimal inversion order in the left–right orientation. This avoided contamination of the spectra with signal from chest skeletal muscle (anterior–posterior orientation) or the liver (head–feet orientation). Triggering was timed at ECG R-wave upslope detection. Respiratory gating causes fluctuations in effective TR, leading to variations in longitudinal magnetization between subsequent acquisitions. If longitudinal magnetization is not equal at the start of all eight acquisitions within one 3D ISIS cycle, the cancellation of unwanted signals in the addition/subtraction scheme is incomplete. Thus, when measuring at TR $< 5 \times T_1$, a constant TR is required to minimize signal contamination. Moreover, measurement at constant TR prevents complex modulations of signal amplitudes that hamper corrections for partial saturation effects. Therefore, we performed unlocalized dummy excitation pulses during respiratory gates to achieve an essentially constant TR of 2 s. The acquisition time was less than 40 min. In a subset of healthy mice ($n = 6$), 3D ISIS was also performed at TR = 15 s; NA = 192 (24 cycles). These measurements were used to verify the partial saturation correction factor obtained with unlocalized saturation recovery experiments.

Figure 1. End-diastolic left ventricular (LV) MR images obtained from a control mouse (A) and a mouse with a transverse aortic constriction (TAC) (B). The constriction is indicated by the arrow. Dilated hypertrophic cardiomyopathy is evidenced by increased LV wall thickness and LV cavity volume in the TAC mouse. Rectangles indicate the voxels selected for 3D ISIS localization with three-dimensional image-selected in vivo spectroscopy (3D ISIS). (C, D) $^{31}$P MR spectra acquired in vivo with 3D ISIS in a healthy mouse heart and a TAC heart, respectively. Myocardial PCr/$\gamma$-ATP, corrected for partial saturation, was lower in TAC mice ($n=8$) compared with healthy controls ($n=9$) (E). Data are expressed as mean ± standard deviation (SD). **$P < 0.01$, $\alpha$, $\beta$, $\gamma$-ATP, $\alpha$, $\beta$- and $\gamma$-phosphate groups in adenosine 5′-triphosphate; 2,3-DPG, 2,3-diphosphoglycerate; PCr, phosphocreatine; Pi, inorganic phosphate.

To compare 3D ISIS localization with 1D localization, we acquired spectra using a pulse-acquire sequence. In 1D ISIS of the anterior myocardial wall (Fig. 2A) in a subset of mice ($n = 6$). Acquisition parameters were kept similar to the 3D ISIS approach, except for NA = 384 (192 1D ISIS cycles) and a slice thickness of 0.1 mm. Furthermore, to obtain spectra solely from the myocardium and to rule out any contamination with signal from LV cavity blood, 3D ISIS was performed with a small voxel ($1 \times 3 \times 3$ mm$^3$) positioned within the anterior myocardial wall (Fig. 2B). The acquisition time was approximately 2.5 h with NA = 3072 (384 cycles).

In addition, spectra from the liver and hind limb skeletal muscle ($n = 3$) were acquired in vivo with respiratory-gated and cardiac-triggered 3D ISIS (Fig. 3) to evaluate the performance of 3D ISIS localization with respect to in vivo $^{31}$P MRS of these tissues, as reported in the literature (20,21).

Finally, to investigate the contribution of blood metabolites to the cardiac $^{31}$P MR spectra acquired in vivo, spectra of fresh blood were measured ex vivo using a pulse-acquire sequence.
A vial ($n = 6$) with approximately 1 mL of blood in EDTA was positioned just over the surface coil and maintained at 37 °C by a heating pad. The parameters were as follows: 1.2-ms 90° sinc excitation pulse; $\gamma$-ATP on resonance; TR = 2000 ms; NA = 512.

**Image analysis**

LV cavity and myocardial wall volumes were quantified by semi-automatic segmentation of the cine images (Pie Medical Imaging, Maastricht, the Netherlands), as described previously (22), yielding LV end-diastolic volume (EDV), end-systolic volume (ESV), stroke volume (SV), ejection fraction (EF) and LV myocardial mass.

**31P MRS data analysis**

Fitting of the metabolite signals to Lorentzian line shapes was performed in the time domain using AMARES in jMRUI (23). The PCr resonance was used as an internal chemical shift reference at 0.00 ppm. The ATP resonances at $-2.48$ ppm ($\gamma$ doublet), $-7.52$ ppm ($\alpha$ doublet) and $-16.26$ ppm ($\beta$ triplet) were fitted with equal amplitudes and LWs within each multiplet, and a
J-coupling constant of 17 Hz. The $\gamma$-ATP LWs (LW$_{\gamma}$-ATP) were constrained relative to the PCr LW (LW$_{PCr}$) according to an empirically determined relation: LW$_{\gamma}$-ATP = LW$_{PCr}$ + 14.85 Hz ($n$ = 63; $r$ = 0.78; $P$ < 0.001). Blood 2,3-diphosphoglycerate (2,3-DPG) resonances obscured the inorganic phosphate (Pi) resonance. Therefore, these signals were fitted with two peaks: one for 2,3-DPG at 5.4 ppm and Pi at 5.4 ppm, and one for 2,3-DPG at 6.3 ppm.

Saturation recovery curves of PCr, $\gamma$-ATP and $\alpha$-ATP were fitted by a mono-exponential function to estimate the corresponding longitudinal relaxation rate constants $R_1$. Mean $R_1$ values were used to determine metabolite $T_1$ values via $R_1 = 1/T_1$.

The in vivo myocardial energy status was expressed as the PCr/$\gamma$-ATP ratio, corrected for partial saturation. Because blood contains ATP, but no PCr (24), signal contamination from blood in in vivo cardiac $^3$P MR spectra may lead to the underestimation of the myocardial PCr/$\gamma$-ATP ratio. Therefore, we evaluated whether the PCr/$\gamma$-ATP ratio in the current work could be affected by blood contamination. The $[\gamma$-ATP/2,3-DPG$_{6.3 \text{ ppm}}]_{\text{blood}}$ ratio in spectra acquired in fresh blood was determined as a measure of the ATP content in blood. The contribution of resonances from blood metabolites to in vivo spectra was assessed by the quantification of the [2,3-DPG$_{6.3 \text{ ppm}}$/ATP]LV ratio in the cardiac 3D ISIS spectra. Next, the relative contribution of signal from ATP in the blood to the ATP signal obtained with in vivo 3D ISIS was calculated as: $[\gamma$-ATP/2,3-DPG$_{6.3 \text{ ppm}}]_{\text{blood}} \times [2,3$-DPG$_{6.3 \text{ ppm}}$/ATP]$_{LV} \times 100\%$.

Validations

To test our in vivo $^3$P MRS method against conventional biochemical assays in ex vivo tissue samples, validation measurements were conducted in a separate cohort of healthy mice ($n$ = 4). Following the acquisition of 3D ISIS-localized myocardial $^3$P MR spectra as described above, the heart was immediately snap frozen on thoracotomy. Myocardial high-energy phosphate concentrations were determined spectrophotometrically as described previously (25).

To monitor the effects of anesthesia on hemodynamics and blood gases, healthy mice ($n$ = 5) underwent cannulation of the carotid artery after the induction of isoflurane anesthesia. The mean arterial pressure (MAP) and heart rate were monitored using a heparinized saline-filled catheter connected to a blood pressure transducer (Baxter TruWave PX600F, Edwards, Irvine, CA, USA), and recorded using LabVIEW 5.1 (National Instruments, Austin, TX, USA), as described previously (26). Each experiment was continued for 1.5 h, and mimicked the experimental conditions of the in vivo $^3$P MRS acquisitions in terms of mouse body temperature, heart and respiratory rates, and anesthesia maintenance, as described above. After 1.5 h, a 100-$\mu$L arterial blood sample was obtained via the cannula and subsequently analyzed using a blood gas analyzer (RAPIDPoint 500, Siemens Healthcare, Erlangen, Germany). Immediately thereafter, the anesthetized mice were sacrificed by snap freezing the heart on thoracotomy for ex vivo spectrophotometric assay of PCr and ATP concentrations (25).

Statistical analyses

Data are reported as the mean ± standard deviation (SD). The statistical significance of differences was analyzed using two-sided paired or unpaired t-tests, as appropriate. The level of significance was set at $P$ < 0.05.

RESULTS

MRI: LV hypertrophy in TAC mice

We assessed the in vivo LV morphology and function from cine MR images to confirm the hypertrophic phenotype and impaired cardiac performance in TAC mice (Table 1, Fig. 1A, B). LV mass was 95% higher in TAC mice compared with healthy
Table 1. Left ventricle (LV) morphology and functional parameters obtained with MRI in control mice and transverse aortic constricted (TAC) mice

<table>
<thead>
<tr>
<th></th>
<th>Control (n = 9)</th>
<th>TAC (n = 8)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>LV mass (mg)</td>
<td>90.0 ± 14.9</td>
<td>176 ± 19.1</td>
<td>***</td>
</tr>
<tr>
<td>LV mass/body weight (mg/g)</td>
<td>3.7 ± 0.6</td>
<td>6.0 ± 0.9</td>
<td>***</td>
</tr>
<tr>
<td>Heart rate (beats/min)</td>
<td>495 ± 50</td>
<td>539 ± 31</td>
<td>NS</td>
</tr>
<tr>
<td>End-diastolic volume (μL)</td>
<td>63.7 ± 10.8</td>
<td>123 ± 26.1</td>
<td>***</td>
</tr>
<tr>
<td>End-systolic volume (μL)</td>
<td>20.8 ± 5.4</td>
<td>94.1 ± 24.8</td>
<td>***</td>
</tr>
<tr>
<td>Stroke volume (μL)</td>
<td>43.0 ± 7.3</td>
<td>28.7 ± 6.6</td>
<td>***</td>
</tr>
<tr>
<td>Ejection fraction (%)</td>
<td>67.6 ± 5.6</td>
<td>23.9 ± 5.2</td>
<td>***</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± standard deviation (SD). Effect of TAC (two-sided unpaired t-test): ***p < 0.001; NS, not significant.

mice (P < 0.001), indicating LV hypertrophy in TAC mice. Concomitantly, EDV (P < 0.001) and ESV (P < 0.001) were higher in TAC mice compared with controls. This translated into a lower SV (−33%, P < 0.001) and EF (−65%, P < 0.001) in TAC mice. Combined, these data illustrate the development of dilated hypertrophic cardiomyopathy with severe systolic dysfunction after 7 weeks of LV pressure overload in TAC mice.

### 31P MRS: in vivo myocardial energy status

Typical $^{31}$P MR spectra acquired with 3D ISIS in a healthy mouse heart and a TAC heart are shown in Fig. 1C, D. Resonances of PCr and ATP are indicated. Inorganic phosphate (Pi, ~5 ppm) was observed by 2,3-DPG arising from blood. The spectral LW for PCr and ATP in myocardial tissue samples (1.00 ± 0.32 versus 0.94 ± 0.14; n = 8; Fig. 5A) matched conventional ex vivo spectrophotometric assays in myocardial tissue (0.93 ± 0.24; n = 6; Fig. 5A). In a subset of healthy mice, both in vivo and ex vivo measurements were performed. Spectrophotometric assays in myocardial tissue mirrored in vivo $^{31}$P MRS measurements of myocardial PCr/γ-ATP ratios in the same hearts (1.00 ± 0.03 versus 0.94 ± 0.14; n = 4; Fig. 5B). Concentrations of PCr and ATP in ex vivo myocardial tissue samples (n = 8) were 18.3 ± 5.7 mmol/kg dry weight and 19.3 ± 2.5 mmol/kg dry weight, respectively.

### Validations

The in vivo PCr/γ-ATP ratio measured with 3D ISIS-localized $^{31}$P MRS in healthy control mice (1.00 ± 0.19; n = 19) matched conventional ex vivo spectrophotometric assays in myocardial tissue (0.94 ± 0.24; n = 8; Fig. 5A). In a subset of healthy mice, both in vivo and ex vivo measurements were performed. Spectrophotometric assays in myocardial tissue mirrored in vivo $^{31}$P MRS measurements of myocardial PCr/γ-ATP ratios in the same hearts (1.00 ± 0.03 versus 0.94 ± 0.14; n = 4; Fig. 5B). Concentrations of PCr and ATP in ex vivo myocardial tissue samples (n = 8) were 18.3 ± 5.7 mmol/kg dry weight and 19.3 ± 2.5 mmol/kg dry weight, respectively.

![Figure 4. $^{31}$P MR spectrum obtained from fresh blood. α-, β-, γ-ATP, α-, β- and γ-phosphate groups in adenosine 5'-triphosphate; 2,3-DPG, 2,3-diphosphoglycerate; PDE, phosphodiester.](image-url)
Mouse hemodynamics and blood gases were measured after 1.5 h of anesthesia to assess the potential effects of the isoflurane anesthetic regimen on the cardiovascular physiology. Throughout these experiments, which mimicked the experimental conditions of the $^{31}$P MRS procedure, MAP (90 ± 3.3 mmHg) and heart rate (497 ± 76 beats/min) remained well within the physiological range for healthy C57BL/6 mice (28). Moreover, after 1.5 h of anesthesia, blood oxygen saturation and other blood gas parameters were normal (Table 2). These data illustrate that the experimental conditions of the in vivo MR protocol have no major influence on mouse hemodynamics or blood gases.

**DISCUSSION**

We have described a non-invasive method to study the in vivo myocardial energy status in healthy and diseased mice using 3D ISIS-localized $^{31}$P MRS. Acquisitions were respiratory gated and cardiac triggered, whilst maintaining steady-state conditions using dummy excitations to ensure accurate localization. We validated our method against conventional biochemical assays of the myocardial PCr/ATP ratio in healthy mice. Data are expressed as mean ± standard deviation (SD). In a subset of healthy mice (n = 4), both $^{31}$P MRS and biochemical assays were performed. The difference in PCr/ATP ratio between the two methods is plotted against the mean per mouse in a Bland–Altman plot (B). Broken lines indicate the limits of agreement (mean ± 2SD) around the mean (full line). ATP, adenosine 5'-triphosphate; PCr, phosphocreatine.

![Figure 5](image)

**Figure 5.** (A) Comparison of in vivo three-dimensional image-selected in vivo spectroscopy (3D ISIS)-localized $^{31}$P MRS measurements (n = 19) and conventional ex vivo spectrophotometric assays (n = 8) of the myocardial PCr/ATP ratio in healthy mice. Data are expressed as mean ± standard deviation (SD). In a subset of healthy mice (n = 4), both $^{31}$P MRS and biochemical assays were performed. The difference in PCr/ATP ratio between the two methods is plotted against the mean per mouse in a Bland–Altman plot (B). Broken lines indicate the limits of agreement (mean ± 2SD) around the mean (full line). ATP, adenosine 5'-triphosphate; PCr, phosphocreatine.

**Table 2.** Hemodynamics and blood gases measured in control mice after 1.5 h of anesthesia (1.2–1.6% isoflurane in a continuous flow of 0.4 L/min of medical air)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value (Mean ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart rate (beats/min)</td>
<td>497 ± 76</td>
</tr>
<tr>
<td>Mean arterial pressure (mmHg)</td>
<td>90 ± 3.3</td>
</tr>
<tr>
<td>pH</td>
<td>7.41 ± 0.03</td>
</tr>
<tr>
<td>pCO$_2$ (mmHg)</td>
<td>31.6 ± 3.5</td>
</tr>
<tr>
<td>pO$_2$ (mmHg)</td>
<td>110.7 ± 4.4</td>
</tr>
<tr>
<td>Total hemoglobin (mM)</td>
<td>9.2 ± 0.2</td>
</tr>
<tr>
<td>O$_2$ saturation (%)</td>
<td>96.2 ± 0.6</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± standard deviation (SD).

The myocardial PCr/ATP ratio in healthy mice was approximately unity, measured both in vivo with $^{31}$P MRS and ex vivo with spectrophotometric assays in the same hearts. This value is on the lower range of the normal PCr/ATP values reported in the literature for humans (overall mean, 1.72 ± 0.26) (30). In humans, heart rate and cardiac work can increase up to three-fold during dobutamine stress (31) or exercise (32). In healthy mice, dobutamine infusion induced a heart rate increase of only approximately 39% (27), whereas running exercise increased mouse heart rates by only 40–90% (33,34). Indeed, it has been suggested that mice may have a lower cardiac energy reserve (35), given the narrower dynamic range of heart rates and cardiac work in mice relative to humans.

Notably, the myocardial PCr/ATP ratio for healthy mice in the current work was lower than the PCr/ATP values obtained in other in vivo $^{31}$P MRS mouse studies (9–11). From measurements of the physiological hemodynamics and blood gases during 1.5 h of anesthesia (28,36), we ruled out any adverse effects of the experimental conditions on mouse cardiovascular physiology that may cause a decreased PCr/ATP ratio. Instead, many technical aspects of localized $^{31}$P MRS acquisition and quantification could contribute to the variability in the MRS-derived PCr/ATP values reported in the literature (30), and should be taken into consideration when comparing between different laboratories (37,38). The three main causes of the apparent discrepancies in literature reports are differences in: (i) correction for partial saturation; (ii) contamination of the spectra by signal from the liver or skeletal muscle tissue; and (iii) contaminating blood in the LV cavity (30). Below, each of these issues is addressed for the current study.

**Partial saturation correction**

For the correction of partial saturation effects, we used metabolite T$_1$ values as determined by unlocalized pulse-acquire saturation recovery experiments. Because the T$_1$ values in chest skeletal muscle could be different from those in cardiac muscle (39), we validated the correction factor in healthy mice by acquiring 3D ISIS-localized spectra from the LV myocardium under fully relaxed conditions. Indeed, the partial saturation correction...
factor derived from unlocalized saturation recovery experiments was in agreement with measurements localized to the heart. This observation validates the assumption (40) that, in the healthy mouse, the $T_1(\text{PCr})/T_1(\gamma\text{-ATP})$ ratio is essentially the same for chest skeletal muscle and myocardium at 9.4 T (11).

**Minimization of signal contamination**

Because 3D ISIS requires multiple acquisitions for signal localization, the method is particularly sensitive to motion artifacts and consequential contamination from tissues surrounding the heart, such as the liver and chest skeletal muscle. Additional contamination ($T_1$, smearing) can be introduced by differences in longitudinal magnetization between subsequent acquisitions within one ISIS cycle as a result of the imperfect flip angle of the excitation pulse combined with a $TR < 5 \times T_1$ (12,13,19). Similar effects occur when $TR$ is not constant between acquisitions, whilst measuring at $TR < 5 \times T_1$. Previous studies in rodents (9) and humans (41–43) using 3D ISIS for cardiac applications did not measure at constant $TR$ for steady-state magnetization, or at fully relaxed conditions. The 3D ISIS sequence presented here uses a respiratory-gated and cardiac-triggered timing strategy to ensure localized inversion of the LV signal at identical cardiac and respiratory phases for all acquisitions, in combination with dummy excitations during respiratory gates to maintain a constant $TR$. In addition, by using the $\gamma$-ATP signal to determine the $\text{PCr}/\text{ATP}$ ratio, we minimized the chemical shift displacement between $\text{PCr}$ and $\text{ATP}$. The $\text{PCr}$ signal was absent in 3D ISIS-localized liver spectra, demonstrating that skeletal muscle located between the surface coil and the voxel of interest did not contaminate the spectra and that signal acquisition was effectively restricted to the liver. Indeed, localized $^{31}$P MRS of the liver (20) will also benefit from the strategy proposed here (44).

Moreover, we demonstrated the effect of potential contamination of the spectra with signal from chest skeletal muscle by comparing 3D ISIS of the whole LV with 1D ISIS of a slice containing the anterior myocardial wall, similar to 1D CSI approaches reported previously (10,45). Localization within the selected slice is realized by surface coil positioning (Fig. 2A), which may introduce signal from the surrounding tissue to the resultant spectrum. The $\text{PCr}/\gamma\text{-ATP}$ ratio obtained with 1D ISIS was consistent with values observed with 1D CSI (10), but two-fold higher than the myocardial $\text{PCr}/\gamma\text{-ATP}$ ratio measured with 3D ISIS.

**Blood contamination**

Blood in the LV cavity contains ATP, but no $\text{PCr}$. If signal from ATP in the blood contributes to the signal acquired from the voxel of interest, the myocardial $\text{PCr}/\text{ATP}$ ratio may be underestimated (46). A correction factor can be applied to account for signal contribution from ATP in the blood to the spectra, which depends on both the amount of ATP in the blood and the amount of blood contributing to the spectrum. We showed that the amount of ATP signal from fresh blood, in terms of $\gamma\text{-ATP}/2,3\text{-DPG}_{0.3}\text{ppm/blood}$, was approximately 20%, which is consistent with previous reports of $^{31}$P MRS studies of blood in humans (24) and mice (9,47). The contribution of signal from metabolites in blood to the in vivo 3D ISIS spectra of the whole LV, estimated via $[2,3\text{-DPG}_{0.3}\text{ppm}/\gamma\text{-ATP}]_{\text{LV}}$, was less than 20%, and was not different between healthy and TAC mice. The high velocity of flowing blood during the acquisition may attenuate the peaks from blood metabolites in spectra obtained in vivo (48). Based on these observations, we estimated that the contribution of signal from ATP in the blood to the ATP signal in in vivo 3D ISIS spectra was only 4%, and concluded that correcting for blood contamination was not necessary in this study. Moreover, spectra obtained with 3D ISIS selecting a small voxel confined to the anterior myocardial wall were similar to those obtained from the whole LV, confirming the minimal contribution of signal from blood to the latter.

**Study limitations**

With our current approach of determining the $\text{PCr}/\text{ATP}$ ratio, it is not possible to detect similar decreases in both $\text{PCr}$ and $\text{ATP}$ concentrations. The absolute quantification of metabolite concentration will therefore be more sensitive to changes in cardiac energy metabolism. Indeed, it has been shown that, in pressure-overload mouse hearts, not only do myocardial $\text{PCr}$ levels drop, but also $\text{ATP}$ concentrations decrease, illustrating the added value of absolute quantification over the $\text{PCr}/\text{ATP}$ ratio (45,49). Nonetheless, the $\text{PCr}/\text{ATP}$ ratio has been used to identify perturbations in myocardial energy homeostasis in various mouse models of disease (16,50,51). Furthermore, a reduced $\text{PCr}/\text{ATP}$ ratio has been shown to be an important indicator of disease severity (16).

A drawback of using single-voxel-localized $^{31}$P MRS of the entire LV is that myocardial energy status cannot be assessed at a regional scale, which is of importance in investigations of myocardial ischemia. In vivo 2D $^{31}$P CSI of the mouse heart (11) would allow for the mapping of myocardial energetics to assess differences between infarcted and remote regions in mouse models of myocardial ischemic insult. Nonetheless, because many preclinical animal studies focus on pathologies that have a global effect on the heart, such as aortic stenosis, diabetes and inborn errors of metabolism, the current 3D ISIS approach for localized $^{31}$P MRS can be a valuable addition to the toolbox of mouse cardiac MR methods (4).

Even at the high magnetic field strength of 9.4 T, we were unable to unambiguously detect and quantify myocardial $P_i$, because the signal was obscured by signal from 2,3-DPG in the blood. Potentially, reliable detection of $P_i$ would provide additional metabolic insights, as decreasing $\text{PCr}$ levels may be mirrored by increasing $P_i$ levels. In addition, the chemical shift of $P_i$ could potentially be used to quantify in vivo myocardial pH. Notably, even in the human heart, $P_i$ is often undetectable, suggesting that myocardial $P_i$ may only be partially MR visible (30).

**CONCLUSIONS**

The present work describes a non-invasive approach to assess myocardial energy status in the in vivo mouse using single-voxel 3D ISIS-localized $^{31}$P MRS, which was validated by conventional biochemical assays in ex vivo myocardial tissue samples from the same hearts. The method encompasses a respiratory-gated, cardiac-triggered 3D ISIS sequence, with dummy excitations during respiratory gates, to ensure a well-defined localization. This method identified differences in high-energy phosphate metabolism between the healthy mouse heart and a widely used model for heart failure, the TAC mouse. Importantly, results were obtained under physiological conditions, which are difficult or impossible to achieve with disruptive methods, such as open-thorax protocols or isolated perfused heart set-ups. Furthermore, the 3D ISIS-localized spectra can be obtained within 40 min, leaving room for...
measurements of cardiac function with MRI during the same experimental session. We anticipate that localized $^{31}$P MRS will provide valuable contributions to preclinical investigations of cardiac disease progression and therapeutic intervention efficacy.

Acknowledgements

We thank Larry de Graaf and Tom R. Geraedts for the design of dedicated hardware, Esther C. M. Kneepkens for contributions to pulse sequence design and Leonie B. P. Niesen for biotechnical assistance. Dr Jeroen A. L. Jeneson is acknowledged for helpful discussions.

This work was supported by the Center for Translational Molecular Medicine, project TRIUMPH (grant number 01C-103), with funding from the Dutch Heart Foundation. S.M.H. and J.J.P. are fellows of the Molecular Medicine, project TRIUMPH (grant number 01C-103), with funding from the Dutch Heart Foundation. Part of this work was supported by the Netherlands Organization for Scientific Research (NWO). We thank Larry de Graaf and Tom R. Geraedts for the design of experimental session. We anticipate that localized $^{31}$P MRS will provide valuable contributions to preclinical investigations of cardiac disease.

REFERENCES


